

Publikationsverzeichnis

1. Gibson, C. M. *et al.* Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. *N. Engl. J. Med.* **375**, 2423–2434 (2016).
2. Cannon, C. P. *et al.* Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. *N. Engl. J. Med.* **377**, 1513–1524 (2017).
3. Valgimigli, M. *et al.* 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. *Eur. Heart J.* **39**, 213–260 (2018).
4. Eikelboom, J. W. *et al.* Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N. Engl. J. Med.* **377**, 1319–1330 (2017).
5. Sabatine, M. S. *et al.* Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N. Engl. J. Med.* **376**, 1713–1722 (2017).
6. Mas, J.-L. *et al.* Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. *N. Engl. J. Med.* **377**, 1011–1021 (2017).
7. Reddy, V. Y. *et al.* 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. *J. Am. Coll. Cardiol.* **70**, 2964–2975 (2017).
8. Fuhrmann-Stroissnigg, H. *et al.* Identification of HSP90 inhibitors as a novel class of senolytics. *Nat. Commun.* **8**, 422 (2017).
9. Baar, M. P. *et al.* Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. *Cell* **169**, 132–147.e16 (2017).
10. Zhu, Y. *et al.* New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. *Aging (Albany, NY)*. **9**, 955–963 (2017).
11. Stone, R. M. *et al.* Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. *N. Engl. J. Med.* **377**, 454–464 (2017).
12. Wei, A. H. & Tiong, I. S. Midostaurin, enasidenib, CPX-351, gemtuzumab, ozogamicin, and venetoclax bring new hope to AML. *Blood* **130**, 2469–2474 (2017).
13. McAlindon, T. E. *et al.* Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. *JAMA* **317**, 1967–1975 (2017).
14. Stone, J. H. *et al.* Trial of Tocilizumab in Giant-Cell Arteritis. *N. Engl. J. Med.* **377**, 317–328 (2017).
15. 2017 ACR/ARHP Annual Meeting Abstract Supplement. *Arthritis Rheumatol. (Hoboken, N.J.)* **69 Suppl 1**, 1–4426 (2017).
16. Taylor, P. C. *et al.* Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N. Engl. J. Med.* **376**, 652–662 (2017).
17. Rheuma: G-BA konkretisiert Leistungen für ambulante spezialfachärztliche Versorgung. *Deutsches Ärzteblatt* (2017). at [https://www.aerzteblatt.de/nachrichten/sw/Ambulante spezialfach%20ärztliche Versorgung?nid=87210](https://www.aerzteblatt.de/nachrichten/sw/Ambulante_spezialfach%20ärztliche_Versorgung?nid=87210)
18. Toth-Manikowski, S. & Grams, M. E. Proton Pump Inhibitors and Kidney Disease - GI Upset for the Nephrologist? *Kidney Int. reports* **2**, 297–301 (2017).
19. Wanner, C. *et al.* Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N. Engl. J. Med.* **375**, 323–34 (2016).
20. Neal, B. *et al.* Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N. Engl. J. Med.* **377**, 644–657 (2017).
21. Cammarota, G. *et al.* European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* **66**, 569–580 (2017).
22. Paramsothy, S. *et al.* Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet (London, England)* **389**, 1218–1228 (2017).

23. Bajaj, J. S. *et al.* Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. *Hepatology* **66**, 1727-1738 (2017).
24. Gopalakrishnan, V. *et al.* Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* **359**, 97-103 (2018).